

Resource Summary Report

Generated by [NIF](#) on Aug 2, 2026

Polysolver

RRID:SCR_022278

Type: Tool

Proper Citation

Polysolver (RRID:SCR_022278)

Resource Information

URL: <https://software.broadinstitute.org/cancer/cga/polysolver>

Proper Citation: Polysolver (RRID:SCR_022278)

Description: Software tool for HLA typing based on whole exome sequencing data and infers alleles for three major MHC class I genes. Enables accurate inference of germline alleles of class I HLA-A, B and C genes and subsequent detection of mutations in these genes using inferred alleles as reference.

Synonyms: POLYmorphic loci reSOLVER, POLYSOLVER

Resource Type: data processing software, data analysis software, software application, software resource

Defining Citation: [PMID:26372948](#)

Keywords: HLA typing, whole exome sequencing data, accurate inference of germline alleles, high precision HLA-typing, alleles of class I HLA-A, B and C genes, detection of mutations, inferred alleles

Funding: Blavatnik Family Foundation ;
NHLBI 1R01HL103532;
NCI 1R01CA155010;
AACR

Availability: Free, Available for download, Freely available

Resource Name: Polysolver

Resource ID: SCR_022278

Record Creation Time: 20220512T050141+0000

Record Last Update: 20260801T190759+0000

Ratings and Alerts

No rating or validation information has been found for Polysolver.

No alerts have been found for Polysolver.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Padul VG, et al. (2025) Assessment of Functional Status of Human Leukocyte Antigen Class I Genes in Cancer Tissues in the Context of Personalized Neoantigen Peptide Vaccine Immunotherapy. JCO clinical cancer informatics, 9, e2400174.

Kayhanian H, et al. (2024) Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancer. Nature genetics, 56(7), 1420.

Zhang H, et al. (2024) Genomic profiling and associated B cell lineages delineate the efficacy of neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma. EBioMedicine, 100, 104971.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer cell, 42(1), 135.

Lee Y, et al. (2023) Characterization of the genomic alterations in poorly differentiated thyroid cancer. Scientific reports, 13(1), 19154.

Filip I, et al. (2023) Pervasiveness of HLA allele-specific expression loss across tumor types. Genome medicine, 15(1), 8.

Thummalapalli R, et al. (2023) Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(21), 4408.

Yin J, et al. (2023) Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. Nature medicine, 29(8), 2068.

Wang S, et al. (2023) SpecHLA enables full-resolution HLA typing from sequencing data. Cell reports methods, 3(9), 100589.

Spain L, et al. (2023) Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways. Cancer discovery, 13(6), 1364.

Semaan A, et al. (2023) Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project. *Cancer research communications*, 3(10), 2062.

Zhang X, et al. (2022) Single-cell sequencing reveals CD133+CD44--originating evolution and novel stemness related variants in human colorectal cancer. *EBioMedicine*, 82, 104125.

Vázquez-García I, et al. (2022) Ovarian cancer mutational processes drive site-specific immune evasion. *Nature*, 612(7941), 778.

Sammut SJ, et al. (2022) Multi-omic machine learning predictor of breast cancer therapy response. *Nature*, 601(7894), 623.

Gatenbee CD, et al. (2022) Immunosuppressive niche engineering at the onset of human colorectal cancer. *Nature communications*, 13(1), 1798.

Nguyen PHD, et al. (2021) Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. *Nature communications*, 12(1), 227.

Claeys A, et al. (2021) Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals. *PLoS genetics*, 17(2), e1009368.

Au L, et al. (2021) Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. *Cancer cell*, 39(11), 1497.

Fangazio M, et al. (2021) Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, 118(22).

Chen J, et al. (2021) In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales. *Briefings in bioinformatics*, 22(3).